Base editing of Ptbp1 in neurons alleviates symptoms in a mouse model of Parkinson's disease.

Autor:	Böck D; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland., Wilhelm M; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland., Mumenthaler J; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland., Carpanese DF; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland., Kulcsár PI; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland., d'Aquin S; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland., Cremonesi A; Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland., Rassi A; Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland., Häberle J; Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland., Patriarchi T; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland., Schwank G; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Jazyk:	angličtina
Zdroj:	ELife [Elife] 2024 Dec 23; Vol. 13. Date of Electronic Publication: 2024 Dec 23.
DOI:	10.7554/eLife.97180
Abstrakt:	Parkinson's disease (PD) is a multifactorial disease caused by irreversible progressive loss of dopaminergic neurons (DANs). Recent studies have reported the successful conversion of astrocytes into DANs by repressing polypyrimidine tract binding protein 1 (PTBP1), which led to the rescue of motor symptoms in a chemically-induced mouse model of PD. However, follow-up studies have questioned the validity of this astrocyte-to-DAN conversion model. Here, we devised an adenine base editing strategy to downregulate PTBP1 in astrocytes and neurons in a chemically-induced PD mouse model. While PTBP1 downregulation in astrocytes had no effect, PTBP1 downregulation in neurons of the striatum resulted in the expression of the DAN marker tyrosine hydroxylase (TH) in non-dividing neurons, which was associated with an increase in striatal dopamine concentrations and a rescue of forelimb akinesia and spontaneous rotations. Phenotypic analysis using multiplexed iterative immunofluorescence imaging further revealed that most of these TH-positive cells co-expressed the dopaminergic marker DAT and the pan-neuronal marker NEUN, with the majority of these triple-positive cells being classified as mature GABAergic neurons. Additional research is needed to fully elucidate the molecular mechanisms underlying the expression of the observed markers and understand how the formation of these cells contributes to the rescue of spontaneous motor behaviors. Nevertheless, our findings support a model where downregulation of neuronal, but not astrocytic, PTBP1 can mitigate symptoms in PD mice. Competing Interests: DB, MW, JM, DC, PK, Sd, AC, AR, JH, TP No competing interests declared, GS G.S. is an advisor to Prime Medicine (© 2024, Böck, Wilhelm et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu